Xiangxue Life Sciences moves into in vivo TCR-T with new partner

Xiangxue Life Sciences has agreed a strategic partnership with Guangzhou-based Damien Vaccines to co-develop in vivo TCR-T therapies, adding fresh momentum to one of the cell-therapy field’s most closely watched next-generation strategies. The collaboration also includes work on mRNA cancer vaccines paired with Xiangxue’s high-affinity TCR-T products for solid tumors.

The move comes as the wider group, linked to Xiangxue Pharmaceutical (SZSE: 300147), faces pressure on revenue, trailing-twelve-month sales were reported at roughly 1.7 billion yuan ($240 million), while the global in vivo cell-therapy market expands quickly. Much of that growth is driven by rising investment in platforms designed to simplify and scale T-cell engineering inside the body.

Xiangxue says its aim is to deliver off-the-shelf in vivo TCR-T products using targeted delivery systems that allow T-cells to be reprogrammed directly in patients. This approach, long discussed as a way to address the high cost and long timelines of ex vivo cell therapy, has gained traction as multinationals explore in vivo technologies through early-stage studies and acquisitions.